Entecavir Global Market Report 2025

The entecavir market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.75 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth during the historical period can be attributed to several factors, including the increase in the incidence of hepatitis B, greater awareness of liver-related diseases, a growing emphasis on personalized medicine, the rise of online shopping for medications, and the improved availability of entecavir.

The entecavir market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth during the forecast period can be attributed to increasing efforts to combat liver diseases, a rising adoption of digital healthcare solutions, improvements in healthcare infrastructure, greater health insurance coverage, and a growing demand for antiviral medications. Key trends during this period include the integration of genetic testing, the use of advanced diagnostic tools, advancements in personalized medicine, the adoption of combination therapies, and progress in monitoring techniques.

The increasing prevalence of liver diseases is expected to drive the growth of the entecavir market in the coming years. Liver diseases encompass a variety of conditions that impair liver function, including infections, genetic disorders, and lifestyle-related issues such as fatty liver, hepatitis, cirrhosis, and liver cancer. The rise in liver diseases is primarily attributed to factors such as viral hepatitis (HBV and HCV), increasing obesity rates, alcohol abuse, and metabolic disorders. Entecavir, an antiviral drug, supports liver disease patients by effectively inhibiting the replication of the hepatitis B virus, reducing viral load, improving liver function, and lowering the risk of cirrhosis and liver cancer. This ultimately helps manage chronic hepatitis B infections and prevents further liver damage. For example, in June 2024, the Cancer Council Victoria reported that 617 individuals were diagnosed with liver cancer in 2022, with 67.9% of cases affecting males. Additionally, the Liver Foundation projected that around 3,000 people are diagnosed with hepatocellular carcinoma (HCC) annually. Therefore, the rising incidence of liver diseases is driving the growth of the entecavir market.

The increasing prevalence of hepatitis B is also expected to boost the entecavir market. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain. If untreated, it can lead to chronic liver disease or liver cancer. The rise in hepatitis B cases is linked to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Entecavir treats hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, reducing viral load, and preventing liver damage. For instance, in January 2025, the UK Health Security Agency reported that approximately 270,000 people in the UK were living with hepatitis B in 2022, and the number of diagnosed cases is expected to double by 2030. Consequently, the growing prevalence of hepatitis B is driving the growth of the entecavir market.

Companies in the entecavir market are advancing clinical trials and innovative drug development for chronic hepatitis B treatment, aiming to improve efficacy and treatment outcomes while reducing resistance and enhancing long-term viral suppression. Clinical trials are essential for evaluating the safety and effectiveness of new treatments. For example, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company, initiated a phase 2 clinical trial for ALG-000184, a capsid assembly modulator being developed for hepatitis B treatment. ALG-000184 works by disrupting the formation of the capsid, the protective shell around a virus’s genetic material. The ongoing study is assessing the long-term effects of ALG-000184, either alone or in combination with entecavir (sold as Baraclude), in patients with chronic hepatitis B. Preliminary results indicate that the combination of ALG-000184 and entecavir led to more significant reductions in viral load compared to entecavir alone, with ALG-000184 maintaining similar effectiveness regardless of its use alongside entecavir. The virus remained suppressed throughout the study in both HBeAg-positive and HBeAg-negative patients.

Major players in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc., HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.

Asia-Pacific was the largest region in the entecavir market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in entecavir report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Entecavir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Entecavir is an antiviral medication used for the treatment of chronic hepatitis B. It works by inhibiting the replication of the hepatitis B virus, which helps lower the viral load. This, in turn, reduces the risk of severe liver damage and complications such as cirrhosis or liver cancer.

The primary forms of entecavir are tablets and oral solution. Entecavir tablets are taken orally and are prescribed for managing chronic hepatitis B (CHB) infection. These tablets are utilized for a range of purposes, including hepatitis B treatment, liver transplantation, and other related conditions. They are available through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The entecavir market research report is one of a series of new reports that provides entecavir market statistics, including the entecavir industry's global market size, regional shares, competitors with an entecavir market share, detailed entecavir market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. This entecavir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.